AR and prostate carcinoma: Together with the literature [59,60,61,62,63,64,65,66,67,68,69,70,71,72], the above data raises the possibility that aberrant sialylation could play a functional role in the acquired resistance of prostate cancer to the second-generation AR antagonist enzalutamide.